Phase 2 dose escalation protocol from 2 mg to 12 mg/week — with side effect management at each stage
Retatrutide requires gradual dose escalation to minimize GI side effects — the primary dose-limiting factor in Phase 2 trials. The standard titration schedule takes 12 weeks to reach the 12 mg/week maintenance dose. This guide covers each stage of the titration, what to expect, and how to manage side effects at each dose level.
Starting dose to establish tolerability. Nausea is most common during this phase. Administer as a once-weekly subcutaneous injection on the same day each week.
First dose increase. GI side effects may temporarily worsen for 1–2 weeks after escalation before subsiding. Maintain this dose for the full 4 weeks before escalating further.
Second escalation. Significant weight loss is typically occurring by this phase. GI side effects usually diminishing compared to earlier phases as the body adapts.
Maximum dose from Phase 2 trials. Mean weight loss of ~24% was observed at 48 weeks at this dose. Phase 3 trials are ongoing to confirm long-term safety and efficacy.
If GI side effects (nausea, vomiting, diarrhea) are significant at any dose level, do not escalate on schedule. Maintain the current dose for an additional 4 weeks. Slower titration is preferable to discontinuation.
An extended titration schedule adds 4 weeks at each dose level, taking 24 weeks to reach 12 mg/week instead of 12. This approach is appropriate for individuals who are particularly sensitive to GI side effects. The weight loss outcomes are not expected to differ significantly with a slower titration — the total dose over time is similar.
| Compound | Start Dose | Max Dose | Titration Duration |
|---|---|---|---|
| Semaglutide | 0.25 mg/week | 2.4 mg/week | ~17 weeks |
| Tirzepatide | 2.5 mg/week | 15 mg/week | ~20 weeks |
| Retatrutide | 2 mg/week | 12 mg/week | ~12 weeks |
The Phase 2 trial titration schedule was: 2 mg/week for 4 weeks, then 4 mg/week for 4 weeks, then 8 mg/week for 4 weeks, then 12 mg/week maintenance. This 12-week escalation period is designed to minimize GI side effects.
The standard Phase 2 titration takes 12 weeks to reach the 12 mg/week maintenance dose. Some protocols allow extending each dose level by 4 weeks if GI side effects are significant.
Starting at a high dose without titration significantly increases the risk of severe nausea, vomiting, and GI distress. Titration is essential for tolerability and is standard in all clinical protocols for GLP-1 class agents.
Yes. If GI side effects are significant at any dose level, maintaining the current dose for an additional 4 weeks before escalating is appropriate. Slower titration is preferable to discontinuation.
All three GLP-1 agents use gradual titration over 12–17 weeks. Retatrutide's Phase 2 schedule (12 weeks to maintenance) is slightly faster than semaglutide's standard 17-week titration to 2.4 mg/week. Tirzepatide typically takes 20 weeks to reach 15 mg/week.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.